Liver disease, especially alcohol related, is increasingly common and is often accompanied by malnutrition as a result of reduced intake, absorption, processing and storage of nutrients. An increase or alteration in metabolic demands also occurs and some patients have high nutrient losses. Malnutrition in all forms of liver disease is associated with higher rates of mortality and morbidity but it is often under recognised and under treated despite the fact that appropriate treatment can improve outcomes. In this review, the causes, consequences and assessment of nutritional status in patients with liver disease are examined, and an approach to best treatment is proposed.

**Causes of malnutrition in liver patients**
Malnutrition in chronic liver disease is multifactorial (see table 1).

**Impaired intake, digestion and absorption of nutrients**
All forms of acute or chronic liver problems may be accompanied by loss of appetite, and the presence of ascites can add striking early satiety. Low sodium diets can be very unpalatable and in alcoholic liver disease (ALD), patients often replace food calories with alcohol calories, or eat poorly due to oesophagitis, gastritis or pancreatitis. Food intake may also be poor with poverty or social isolation.

A degree of maldigestion is common in cirrhosis as a result of decreased bile salt solubilisation, and severe maldigestion is common in ALD with pancreatic damage. Malabsorption, with or without maldigestion, also occurs in alcoholics due to the toxic effects of alcohol on small intestinal ultrastructure and brush border enzymes. Many ALD patients therefore have rapid intestinal transit, increased mucosal permeability and impaired salt and water absorption. Absorptive problems are also seen with portal hypertension from any cause due to congestion of the intestinal mucosa.

**Impaired nutrient storage**
The liver is the main store for many nutrients, particularly water soluble vitamins. Loss of storage capacity can therefore exacerbate micronutrient deficiencies caused by low or unbalanced dietary intakes. The best known example is that of thiamine deficiency in ALD although in this case there is actually a combination of poor storage, inadequate dietary intake, poor jejunal absorption and even alcohol promoted urinary loss. Nearly all ALD cirrhotics are therefore thiamine deficient and at high risk of Wernike Korsakoff syndrome.

**Impaired nutrient synthesis and altered nutrient demands**
Liver cirrhosis particularly affects protein metabolism with reductions in synthesis of transport proteins such as albumin. This is caused by a combination of decreased functional liver mass and alterations in amino acid (AA) demands. Reduced glycogen storage also increases AA needs for gluconeogenesis while ongoing inflammation alters the pattern of AA requirements, precipitating specific AA shortages. This problem is then made worse by a reduced capacity for transamination reactions which should allow the liver to generate AAs in short supply from those available. As a consequence of all of the above, patients with cirrhosis need considerably higher minimum daily protein intakes of around 60 g (1.2 g/kg/day) to maintain nitrogen balance rather than the 35 g (0.5 g/kg/day) needed by healthy individuals; so contrary to the popular misconception that all liver patients need low protein diets, high protein intakes are required if any improvement in lean tissue mass is to be achieved. Indeed, dietary protein retention remains efficient at much higher rates of provision than in normal individuals, with benefits seen at levels of up to 2.0 g/kg/day, without adverse effects. Nevertheless, we believe...
that higher levels of protein provision should probably be avoided in acute liver disease or decompensated chronic liver disease.

Levels of overall energy demands in cirrhotic liver disease are subject to debate with resting energy expenditure (REE) studies showing conflicting results. The largest study to date in 473 patients showed that 34% of cirrhotics were hypermetabolic on indirect calorimetry but the causes of elevated REE were unclear and unrelated to clinical or biochemical assessments of impaired liver function. The increased energy expenditure may therefore reflect extrahepatic events in some liver disease patients such as the systemic inflammatory response. Overt or hidden infection also increases REE in cirrhotics and the presence of ascites per se seems to contribute since falls in REE are seen with paracentesis. Nevertheless, in one study hypermetabolism was still present in some patients 1 year after insertion of transjugular intrahepatic portosystemic shunts, even though ascites had resolved.

**Abnormal nutrient losses**
Cirrhotic patients may lose both macro- and micronutrients from diarrhoea or gastrointestinal blood loss and renal losses of electrolytes are also higher than normal due to secondary hyperaldosteronism, sometimes exacerbated by diuretics. Renal losses of micronutrients, such as thiamine, are also increased, and paracentesis leads to large electrolyte and protein losses.

**The prevalence of malnutrition in liver patients**
Malnutrition is very common in chronic liver disease and is seen in about 20% of patients with compensated cirrhosis and in up to 60% of those with advanced disease. It is therefore more common than in cancer patients and is almost inevitable in patients awaiting liver transplantation. The aetiology of the cirrhosis does not affect the severity of overall malnourishment but does influence the susceptibility to particular deficiencies—for example, folate depletion effects up to 80% of ALD patients while cholestatic patients are more likely to develop fat soluble vitamin deficiencies.

**The consequences of malnutrition in liver patients**
Malnutrition appears to contribute to many of the complications of cirrhosis but it is difficult to assess the independent effects since progressive liver insufficiency is usually associated with both declining nutritional status and increased complications. Multivariate analysis has yielded conflicting results, especially as examination of multiple variables has meant that many studies are underpowered. For example, although Alberino and colleagues examined 212 hospitalised patients for 2 years found that malnutrition was an independent predictor of survival, Merli and colleagues in a larger study failed to show this association. It therefore remains unclear whether malnourished cirrhotics are more likely to die as a result of compromised nutritional status or whether patients who die are simply more likely to be malnourished. Whatever the cause of the relationship, however, poor nutritional status is associated with very poor outcomes.

Cirrhosis has a dramatic effect on body composition. Half of all patients are protein depleted and have reduced muscle function; this is significantly more prevalent in ALD and is higher in men (63%) than in women (28%). Møller and colleagues studied 55 patients with cirrhosis presenting with their first episode of variceal bleeding, using a Cox regression model to look at 55 different characteristics. Poor nutritional status emerged as one of five variables independently associated with a higher risk of rebleed or death (p<0.00005). Similarly, Kalaitzakis and colleagues studied 128 patients with encephalopathy and found significantly higher rates in malnourished compared with better nourished patients, especially if weight loss was recent, and although Sörös and colleagues failed to confirm this relationship in 223 patients with non-alcoholic cirrhosis, this may have been because assessment of recent weight loss was not included. Maldigested patients undergoing transplantation have higher short term postoperative complications, including increased infection rates, days in the intensive care unit, use of blood products and hospital stays. Longer term graft survival also appears reduced.

**Identifying malnutrition in liver patients**
Although signs of malnutrition may be obvious in many liver patients, nutritional risk can be easily overlooked, and a high index of clinical suspicion is always appropriate. The National Institute for Health and Clinical Excellence (NICE) recommends that all patients should be screened for malnutrition at presentation but both screening and more detailed nutritional assessment are fraught with difficulties due to abnormalities in body weight and composition that are present in most liver patients.
Liver disease often results in sodium and water retention, increasing apparent body weight. This may be obvious as in patients with ascites or oedema but may also be present in patients without clinically overt fluid retention. The changes in protein metabolism described above also lead to relative lean tissue wasting and most patients with severe liver disease have very abnormal body compositions. Defining these abnormalities accurately outside of research settings is difficult and there are no gold standards. However, the approaches in table 2 are often used.

Treat malnutrition in liver patients—what to give

Taking active steps to treat malnutrition in stable liver patients using either diet or some form of nutrition support is common sense but it is difficult to prove it is beneficial. Although liver patients must obviously eat or be fed in order to survive, obtaining ethical approval for randomised controlled trials (RCTs) of nutrition support versus continued relative starvation will always be problematic. Furthermore, even if ethical approval were granted, recruiting suitably ‘informed’ patients would be virtually impossible. As a result, studies of nutrition in liver patients have tended to be small, comparing standard feeding with provision of some supplementary intake. This leads to reduced effect size and consequent difficulty in evaluating the true importance of nutritional care. Nevertheless, individual trials of nutrition in stable liver patients do indicate treatment benefit (see table 3).

Treat malnutrition, let alone undertaking trials, is even more difficult in acute–severe or decompensated–chronic liver disease with potential sepsis, renal impairment, ascites, sodium restrictions and encephalopathy. The optimal route for providing nutritional support in such patients tends to change with time, with enteral tube or even parenteral nutrition needed early in the course of illness, moving to oral supplements and/or meals as things improve. Furthermore, optimal target levels for feeding should also vary with disease progress, and for reasons outlined below, we believe that initial low levels may be better when patients are decompensated or acutely ill, followed by a move to maintenance levels as they begin to recover and high levels once the patients are stable and able to regain lean body mass. These ideas, however, are not accepted by all authorities and some guidelines recommend target levels of early feeding in sick patients that we think are too high.

Energy and protein intakes

In malnourished cirrhotic patients, most guidelines suggest an intake of 35–40 kcal/kg/day with a protein intake of at least 1.2–1.5 g/kg/day. This seems sensible as it will maximise positive nitrogen balance and accrual of lean tissues, and so hopefully improve overall health status. However, feeding acutely ill patients with either acute disease or acute-on-chronic problems at such high levels may not be helpful for even though energy demands are raised and some evidence suggests that high nitrogen provision achieves best nitrogen balance, high levels of feeding do not equate to better patient outcomes and logic suggests commencement at lower levels. The thinking behind this apparent paradox is that providing nutrients that cannot be fully utilised by sick patients could potentially add problems of hyperglycaemia, lipaemia and refeeding to ongoing metabolic stress, especially if pre-existing malnutrition, vitamin and electrolyte deficiencies or liver dysfunction limit a patient’s overall metabolic capacity to handle exogenous substrates. Furthermore, as the systemic inflammatory response and immune expansion lead to unusual AA demands, higher levels of protein provision will cause a surfeit of unwanted AAs that demand metabolic disposal. We therefore recommend following the current NICE guidance that feeding in all seriously ill patients is introduced at rates meeting about 50% of maintenance energy and protein requirements, while meeting full electrolyte, micronutrient and fluid needs. We estimate maintenance energy requirements using a value of 120% of resting metabolic rate (calculated using, for example, Schofield’s equation) and maintenance levels of protein as approximately 0.7 g protein/kg/day. Feeding levels can then be built up after 48 h to meet full maintenance needs, with later

---

**Table 2 Nutritional assessment techniques in patients with liver cirrhosis**

<table>
<thead>
<tr>
<th>Assessment technique</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Malnutrition Universal Screening Tool</td>
<td>Although not designed for cirrhotic patients, can make allowances for ascites and oedema if the problem is recognised but this may not happen in practice.</td>
</tr>
<tr>
<td>Subjective Global Assessment and the Prognostic Nutritional Index</td>
<td>Both have been used to assess nutritional status but tend to underestimate prevalence.</td>
</tr>
<tr>
<td>The Royal Free Hospital Global Assessment</td>
<td>This is reproducible and valid against measures of body composition. It can also help predict survival.</td>
</tr>
<tr>
<td>Mid upper arm muscle circumference (MAMC)</td>
<td>Assesses lean tissue status and is little affected by salt and water retention. It is derived from mid upper arm circumference (MAMC) and triceps skinfold thickness (TSF) as follows: MAMC = MAC – (3.14 x TSF).</td>
</tr>
<tr>
<td>Hand grip strength</td>
<td>Coupled with measures of arm circumference, has been shown to have a sensitivity of 94% and negative predictive value of 97% in identifying depleted body cell mass in cirrhics. Grip strength is also the best modality for predicting major complications at 1 year. Nevertheless, it is reliant on patient volition and rarely used in clinical practice.</td>
</tr>
<tr>
<td>Bioelectrical impedance analysis</td>
<td>Recommended as a reliable bedside tool by the European Society for Clinical Nutrition and Metabolism but has considerable limitations in liver disease patients with their abnormal salt and water distribution.</td>
</tr>
</tbody>
</table>
Further increases to replenishment feeding at or above the levels suggested for stable cirrhotic patients. Even lower commencement feeding rates and more cautious rates of increase may be warranted in patients at high risk of refeeding problems.

Feeding patients with encephalopathy raises further questions. For many years, conventional wisdom was to provide low protein diets to limit levels of circulating nitrogenous metabolic products that may contribute to the neurotoxicity. However, most studies actually suggest that low protein diets have little or no effect on encephalopathy but fell out of common practice with encephalopathy and may actually cause harm through worsening nutritional status. We therefore recommend that patients with encephalopathy are offered the same levels of protein as other liver patients—that is, relatively high levels if otherwise stable but lower initial levels if very unwell.

Treatment with supplementary branched chain amino acids (BCAAs) was also thought to benefit patients with encephalopathy but fell out of common practice after a Cochrane meta-analysis in 2003 showed no convincing benefit. More recently, however, the possibility that BCAAs are of benefit in relation to other aspects of liver disease has been raised, with an Italian multicentre RCT of 174 patients with advanced cirrhosis performed over 1 year showing lower rates of hospital admission, reduced Child–Pugh scores and improved quality of life. Furthermore, a larger prospective multicentre RCT in advanced cirrhosis also demonstrated benefit from BCAA supplementation over a 2 year period in terms of death, development of liver cancer, variceal bleeding and progression of liver failure. However, further work is needed to confirm these potentially important findings.

Non-protein energy

There is very little published evidence on optimal ratios of glucose to lipid energy that should be given to malnourished patients with liver disease. The current European Society for Clinical Nutrition and Metabolism guidelines suggest that glucose should provide 50–60% of non-protein energy and lipid about 40–50%. However, the recommendation is based on two small studies both aimed at treating hepatic encephalopathy with BCAAs in hospitalised patients.

There is some evidence which supports the use of newer fat emulsions that have a lower content of n-6 unsaturated fatty acids, which potentially renders them less suppressive to leucocyte and immune function.

Electrolytes and minerals

Most patients with severe acute or chronic liver disease have derangements in electrolyte and mineral balance that need to be monitored closely. Hyperaldosteronism, triggered by vasodilatation and enhanced by defective hepatic aldosterone metabolism, is perhaps the most common problem, and can lead to very severe sodium and water retention. However, the practice of imposing very tight restrictions on sodium provision from diet or other routes is no longer followed by most units as restrictions of greater than about 90 mmol/day make food unpalatable and hence reduce overall nutrient intakes.

Renal failure, secondary to hepatorenal syndrome, is also common in liver patients and may force severe restrictions on potassium, calcium and phosphate intakes. Conversely, refeeding syndrome is a potential problem in some liver patients who then need very generous potassium, phosphate and magnesium provision. Following the NICE refeeding guidance, feeding regimens from as little as 10 kcal/kg/day, building up to maintenance levels over 4–7 days, with careful monitoring and replacement of electrolytes, may be needed.

Micronutrients

Provision of adequate micronutrients is as important as provision of macronutrients and, indeed, if not undertaken may limit metabolic utilisation of protein.

### Table 3 Trials demonstrating benefit of nutritional intervention

<table>
<thead>
<tr>
<th>Type of nutritional support</th>
<th>Authors</th>
<th>Intervention</th>
<th>Main outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteral</td>
<td>Cabre et al</td>
<td>RCT comparing tube feeding with standard diet (2115 kcal/day) in patients with severe malnutrition</td>
<td>Significant reduction in mortality as inpatient (12% vs 47%)</td>
</tr>
<tr>
<td>Hirsch et al</td>
<td>1000 kcal (34 g protein) daily supplement compared with placebo</td>
<td>Reduction in hospitalisation</td>
<td></td>
</tr>
<tr>
<td>Bunout et al</td>
<td>Intake of 50 kcal/kg/day and 1.5 g protein/kg/day compared with standard diet</td>
<td>Non-significant reduction in mortality</td>
<td></td>
</tr>
<tr>
<td>Kearns et al</td>
<td>Intake of 167 kcal/kg/day and 1.5 g protein/kg/day</td>
<td>Improvement of surrogate markers of liver disease, no significant reductions in primary end points</td>
<td></td>
</tr>
<tr>
<td>Parenteral</td>
<td>Wicks et al</td>
<td>Comparison between enteral and parenteral feeding immediately post-OLT</td>
<td>No difference between two groups</td>
</tr>
<tr>
<td>Branch chain amino acid</td>
<td>Muto et al</td>
<td>BCAA (12 g/day for 2 years) oral supplement RCT</td>
<td>Significant reduction in primary outcome (mortality, HCC, variceal bleed and progression of disease)</td>
</tr>
<tr>
<td>Marchesini et al</td>
<td>BCAA oral supplement RCT</td>
<td>Significant reduction in hospital admissions and surrogate markers of nutrition</td>
<td></td>
</tr>
</tbody>
</table>

BCAA, branched chain amino acid; HCC, hepatocellular carcinoma; OLT, orthotopic liver transplantation; RCT, randomised controlled trial.
carbohydrate and fat. Alcoholic liver patients are particularly prone to deficiencies in folate, vitamin C and thiamine while patients with cirrhosis of any origin, especially those with cholestatic liver disease, are at particular risk of developing fat soluble vitamin deficiencies. Vitamin D deficiency occurs frequently as a result of both inadequate diet and malabsorption and results in osteoporosis which is evident in 40% of patients undergoing transplantation. Vitamin A deficiency and night blindness are also documented in cirrhosis, and some patients with ALD develop frank zinc deficiency with orogenital skin rashes.

Measurement of micronutrients in the acute setting is usually unrewarding due to the effects of the acute phase response on circulating levels and the time involved in getting results back. We therefore recommend that all patients are given balanced multivitamin and trace element preparations with specific carbohydrate and fat. Alcoholic liver patients are particularly prone to deficiencies in folate, vitamin C and thiamine while patients with cirrhosis of any origin, especially those with cholestatic liver disease, are at particular risk of developing fat soluble vitamin deficiencies. Vitamin D deficiency occurs frequently as a result of both inadequate diet and malabsorption and results in osteoporosis which is evident in 40% of patients undergoing transplantation. Vitamin A deficiency and night blindness are also documented in cirrhosis, and some patients with ALD develop frank zinc deficiency with orogenital skin rashes.

Measurement of micronutrients in the acute setting is usually unrewarding due to the effects of the acute phase response on circulating levels and the time involved in getting results back. We therefore recommend that all patients are given balanced multivitamin and trace element preparations with specific
supplementation of thiamine and folate in ALD patients. Pabrinex (Link Pharmaceuticals Ltd, Horsham, UK) is useful as an intravenous, thiamine containing preparation but is often used as a generic ‘vitamin fix’ which is not entirely appropriate as it does not contain folic acid, which is one of the commonest deficiencies seen in liver patients. It also contains no fat soluble vitamins or trace elements.

**Treating malnutrition in liver patients—how to provide support**

Figure 1 illustrates a sequential approach to both the method of providing nutritional support and the level of feeding based on our own clinical practice.

**Dietary counselling, special menus and oral nutritional supplements**

In practice, achieving significant changes in oral intake through dietary counselling and special menus alone can be difficult. Consuming small meals should be encouraged as many patients complain of early satiety, particularly those with ascites, and the ‘little and often’ approach, especially with a late evening carbohydrate snack, has also been shown to improve nitrogen balance in cirrhotic patients, probably by limiting the demands on AAs for gluconeogenesis.31

Oral nutritional supplements are not necessarily better than adequate dietary counselling in improving clinical outcome in malnourished liver patients but they do offer immediate simple means of increasing oral intake.32 Higher protein formulations can be helpful in meeting high protein requirements, and in a study by Hirsch and colleagues,33 of 51 outpatients with decompensated ALD treated with oral nutritional supplements for 1 year, improvements in nutritional parameters and a reduced frequency of hospitalisation were seen.

**Enteral tube feeding**

Enteral tube feeding (ETF) is frequently needed in hospitalised patients because sick patients usually fail to meet even modest nutritional targets. Cabre et al in an RCT demonstrated a reduction in mortality (47% vs 12%) in hospitalised (malnourished) cirrhotic patients treated with ETF and several other RCTs have shown that tube feeding can reduce markers of disease severity and possibly reduce mortality.13-35

Although there is often concern that the passage of a nasogastric tube may lead to rupture and bleeding from oesophageal varices, especially after an acute bleed, several studies suggest that this is not the case.34-36 Mere suspicion of oesophageal varices should not therefore delay ETF although acute bleeding should be controlled before the passage of the tube.

**Parenteral nutrition**

Parenteral nutrition should be reserved for patients who are unable to receive or tolerate oral or enteral feeding. In practice, parenteral nutrition is often unworkable because patients pull out central venous catheters as a result of encephalopathy, and it is associated with high rates of central venous catheter infection, which is particularly concerning in cirrhotic patients with impaired immunity. Parenteral nutrition itself can also cause a number of problems with the liver, both in the short and longer term that are beyond the scope of this review, which impair liver function and therefore worsen pre-existing liver disease in cirrhotic patients.

**Conclusions**

Malnutrition is very common in liver disease and gets worse with the severity of the underlying liver problem. Poor nutritional status is associated with a worse prognosis with respect to mortality, encephalopathy, variceal bleeding and infection. It is generally easy to recognise but often overlooked. Simple screening tools can highlight risk, and other measurements are useful as prognostic indicators. It is important that nutrition is provided in appropriate amounts at appropriate stages of the clinical course, especially in patients who are metabolically unstable with poorly functioning livers. There is evidence that careful nutritional support is beneficial, and by implementing a targeted practical approach in clinical settings, improvements in patient outcomes can be seen.

**Competing interests** None.

**Provenance and peer review** Commissioned; not externally peer reviewed.

**References**


